Evolution of the Monro-Kellie Doctrine from Static Intracranial Pressure to Dynamic Intracranial Physiology: A Critical Review of the Monro-Kellie 1.0 Through 4.0 Framework and Its Implications for Contemporary Neurocritical Care

Article information

Abstract

INTRODUCTION

Since Alexander Monro secundus first articulated the principle of intracranial volume constancy in 1783, the Monro-Kellie doctrine has served as the foundational framework upon which modern neurosurgery and neurocritical care have been constructed1,2). The doctrine’s formulation—that the total volume of brain parenchyma, intracranial blood, and cerebrospinal fluid (CSF) within the non-distensible cranium must remain constant—has guided the development of ventriculostomy, osmotherapy, decompressive craniectomy, and virtually every intervention targeting intracranial hypertension3,4). Yet, as Weed cautioned in 1929, upon the doctrine’s “truth or relative untruth, depend many of the critical procedures in the surgery of the central nervous system”5). Two centuries of clinical experience have exposed fundamental limitations in this static, compartmentalized view, which fails to capture the dynamic hemodynamic reality within the cranial cavity, where approximately 700 mL/min of blood flows through a compartment containing only 100–130 mL of intravascular volume at any given moment6). It provides no mechanistic explanation for conditions such as idiopathic intracranial hypertension (IIH) or normal pressure hydrocephalus (NPH), where intracranial pathology manifests without classical mass lesions7-9). These limitations have catalyzed a series of conceptual revisions, systematically designated MK 1.0 through MK 4.0, reflecting an evolutionary trajectory from static volume equilibrium to dynamic intracranial physiology6,9,10). This review selects literature organized based on the authors’ perspectives and provides a critically appraised synthesis of this evolution and its transformative implications for contemporary neurocritical care practice.

THE CLASSICAL MONRO-KELLIE DOCTRINE (MK 1.0): FOUNDATIONS AND CONSTRAINTS

Monro’s 1783 hypothesis that the cranium constitutes a rigid container with constant blood volume was empirically validated by George Kellie in 1824 through systematic autopsy examinations demonstrating consistent cerebral venous blood volume regardless of the mode of death1,2,6). John Abercrombie independently corroborated these findings, demonstrating that the intact skull prevented cerebral exsanguination even when peripheral circulation was depleted. The doctrine’s tripartite structure was completed when Burrows incorporated CSF as the third intracranial component in 1846, culminating in Cushing’s 1926 formulation: “with an intact skull, the sum of the volumes of brain, blood, and CSF is constant”3,6).

The clinical operationalization of MK 1.0 was fundamentally advanced by Langfitt and colleagues’ demonstration of the exponential intracranial pressure-volume relationship, introducing intracranial compliance (ICC)—defined as ΔV/ΔP11). Marmarou further refined this through the pressure-volume index (PVI)—the volume required to produce a tenfold increase in ICP—providing a quantitative metric of compensatory capacity, with normal values of ~26 mL contrasting sharply with values ≤13 mL in patients with exhausted compliance12). The cerebral perfusion pressure (CPP) paradigm, formalized as CPP = MAP – ICP by Miller and Langfitt, became the cornerstone of neurocritical care protocols, with guidelines recommending CPP maintenance above 60–70 mmHg13-16). However, as Johnston and Rowan demonstrated (r = 0.98 correlation of ICP with cortical venous pressure), this equation implicitly assumed no independent venous contribution, establishing what Wilson would later characterize as a misleading “arterial-centric” paradigm6,17).

The classical doctrine harbored several fundamental limitations. The “equal weighting” of each compartment dramatically misrepresented physiological reality, given the 2,000-fold disparity between CSF production (0.35 mL/min) and cerebral blood inflow (~700 mL/min)6). It treated the cranium as a passive container and its contents as inert compartments, providing no framework for understanding IIH, NPH, or microgravity-associated visual impairment2).

MONRO-KELLIE 2.0: THE VASCULAR-VENOUS PARADIGM

In 2016, Wilson published a transformative review demonstrating that the static doctrine systematically obscured the dominant role of dynamic cerebrovascular hemodynamics—particularly venous outflow—in determining moment-to-moment ICP6). Intracranial blood volume of 100–130 mL, distributed across arterial (15%), venous (40%), and microcirculatory (45%) compartments, exists in continuous rapid turnover equivalent to 9–11 seconds of blood inflow. CSF volume (~75 mL) represents only 5 seconds of blood inflow equivalent. Thus, acute ICP dynamics are overwhelmingly dominated by the imbalance between arterial inflow and venous outflow6,18).

Wilson provided the first systematic taxonomy of venous outflow limitation conditions. Intracranial causes include focal sinus compression, bilateral transverse sinus stenosis (found in up to 90% of IIH patients), dural sinus thrombosis, and diffuse venous compression from brain swelling creating an internal Starling-type resistor6). Extracranial causes include cervical collar use (increasing ICP from ~4.5 to 14.5 mmHg), positive pressure ventilation and PEEP, and abdominal compartment syndrome, with decompressive laparotomy reducing otherwise refractory ICP from 27.5 to 17.5 mmHg in one series6,19). Cerebral venous drainage asymmetry, with right-sided transverse sinus dominance in ~40% of individuals, creates differential vulnerability to venous obstruction—a factor routinely overlooked in clinical practice6).

The clinical implications of MK 2.0 were far-reaching: it provided a coherent pathophysiological framework for IIH, challenged universal cervical collar application in brain-injured trauma patients, explained the paradox of ICP elevation during aggressive fluid resuscitation aimed at CPP maintenance, and provided the mechanistic basis for microgravity-associated visual impairment in astronauts, where absence of gravitational assistance for cranial venous drainage produces chronic cerebral venous hypertension6,7,20).

MONRO-KELLIE 3.0: BRAIN TISSUE BIOMECHANICS AND CALVARIAL PLASTICITY

In 2019, Mangalore et al. used voxel-based morphometry (VBM) without normalization to examine brain tissue distribution in IIH and NPH patients9). Despite diametrically opposed clinical presentations, total intracranial volume distributions were comparable to controls; what differed was the spatial morphology of brain parenchyma. They proposed that IIH and NPH represent “opposite sides of the same coin”: in IIH, centrifugal forces from increased venous back-pressure produce tissue compression; in NPH, centripetal forces from abnormal CSF dynamics cause ventricular enlargement9). These changes reflect viscoelastic deformation rather than simple volume displacement—a mechanism outside the scope of MK 1.0 or 2.0.

In 2022, Benson et al. challenged the doctrine’s most axiomatic assumption by demonstrating through comprehensive neuroimaging that the calvaria undergoes measurable expansion and remodeling in response to chronic intracranial pressure alterations, proposing the skull as a fourth dynamic component7). While primarily relevant to chronic conditions, this calvarial plasticity represents an important conceptual advance. Collectively, MK 3.0 effected a transition from volume-based to mechanics-based reasoning: the brain is a viscoelastic tissue capable of deformation, CSF dynamics produce measurable morphological changes even at “normal” ICP values, and the cranium itself is a living bone structure capable of structural response to sustained pressure alterations (Fig. 1).

Fig. 1.

Evolutionary trajectory of the Monro-Kellie doctrine from MK 1.0 (static volume equilibrium, 1783–1926) through MK 2.0 (dynamic vascular-venous paradigm, 2016), MK 3.0 (brain tissue biomechanics and calvarial plasticity, 2019–2022) to MK 4.0 (integrative dynamic paradigm incorporating cerebrovascular autoregulation, glymphatic system function, and intracranial compartment syndrome concept, 2025). Key conceptual transitions are summarized in the lower panel.

MONRO-KELLIE 4.0: THE INTEGRATIVE DYNAMIC PARADIGM

Intracranial Compartment Syndrome

The clinical capstone of MK 4.0 is Intracranial Compartment Syndrome (ICS)—defined by the coexistence of exhausted intracranial compliance and brain tissue hypoxia, irrespective of absolute ICP values10). ICS recognizes a clinical reality that experienced neurointensivists have long observed: patients may deteriorate catastrophically despite “normal” ICP when compensatory reserve is exhausted. Central to ICS diagnosis is the shift from absolute ICP values to ICP waveform morphology as biomarker: the P2/P1 ratio (where P2 > P1 indicates decreased compliance), the RAP index (approaching +1 indicating exhausted reserve), and time-to-peak analysis10,38,39). Brasil et al. validated the B4C noninvasive sensor, which detects micrometric cranial bone deformations, demonstrating strong correlation with invasive ICP waveform parameters (AUROC 0.9 for detecting P2/P1 ≥ 1 and predicting ICP > 20 mmHg)38) (Fig. 2).

Fig. 2.

The Monro-Kellie 4.0 framework: dynamic intracranial components and their determinants. The three pillars of MK 4.0—cerebrovascular autoregulation (Pillar 1), the glymphatic system (Pillar 2), and compensatory reserve (Pillar 3)—interact bidirectionally to determine intracranial dynamics. The central cranial vault diagram shows the spatial relationships among brain parenchyma, CSF, and vascular compartments. Venous outflow dynamics (MK 2.0 contribution) and multimodal monitoring tools (right panel) with B-ICONIC thresholds are integrated. Convergence of all three pillars defines the Intracranial Compartment Syndrome (ICS, bottom center) and identifies therapeutic targets (bottom right).

THE B-ICONIC CONSENSUS AND NONINVASIVE MONITORING

The Brussels International Consensus on Non-Invasive ICP Monitoring (B-ICONIC, 2025), produced by 41 international experts using modified Delphi methodology supported by systematic reviews with meta-analysis, provided 34 recommendations (32 strong, 2 weak) across three domains40). Key actionable thresholds include: Neurological Pupil Index (NPi) ≤ 3 prompting treatment escalation; optic nerve sheath diameter (ONSD) ≥ 6 mm suggesting ICP ≥ 20 mmHg; and transcranial Doppler pulsatility index ≥ 1.4 indicating elevated cerebrovascular resistance40-42). A multimodal approach requiring at least two concordant noninvasive modalities is recommended40).

MK 4.0 envisions seamless neuromonitoring from the emergency department through the ICU. In the emergency setting, automated pupillometry, ONSD ultrasound, noninvasive ICP waveform analysis, and transcranial Doppler enable rapid compliance assessment before invasive monitoring is available10). When invasive monitoring is unavailable, noninvasive assessments performed at least three to four times daily can track compliance trends10,43). For the estimated 69 million individuals sustaining TBI annually worldwide—the vast majority in low- and middle-income countries—this framework represents a potentially transformative advance in equity of care (Fig. 3).

Fig. 3.

ICP pulse waveform morphology as a biomarker of intracranial compliance and the MK 4.0 clinical decision algorithm. (A) Progressive changes in ICP waveform morphology from normal compliance (P1 > P2) through reduced compliance (P2 ≈ P1) to exhausted compliance (P2 >> P1), reflecting the transition from compensated to decompensated intracranial dynamics. (B) The MK 4.0 clinical decision algorithm integrating noninvasive multimodal assessment in the emergency department (Step 1) through urgent ICU continuous monitoring (Step 2) to treatment escalation when Intracranial Compartment Syndrome criteria are met (Step 3). (C) B-ICONIC consensus noninvasive monitoring thresholds for treatment escalation with corresponding evidence strength. B-ICONIC: Brussels International Consensus on Non-Invasive ICP Monitoring; DC: Decompressive craniectomy; ED: Emergency department; ELD: External lumbar drainage; EVD: External ventricular drainage; ICS: Intracranial compartment syndrome; NPi: Neurological pupil index; ONSD: Optic nerve sheath diameter; PI: Pulsatility index.

CLINICAL APPLICATIONS AND THERAPEUTIC IMPLICATIONS

In TBI management, MK 4.0 addresses the disconnect between ICP reduction and functional outcome observed in the DECRA and RESCUEicp trials: ICP is a biomarker of secondary injury, not the injury itself, and managing the biomarker without understanding underlying dynamics may be insufficient or counterproductive23,28,44-46). The framework identifies factors routinely overlooked in standard assessment, including cranial vault thickness variability, venous anatomical variants, venous thrombosis complicating skull fractures, and impaired glymphatic circulation producing shift edema10).

In SAH, the shift edema hypothesis provides mechanistic rationale for early CSF drainage strategies including cisternostomy, EVD, and early lumbar drainage as interventions targeting glymphatic patency beyond simple pressure reduction10,36). For malignant middle cerebral artery (MCA) infarction, autoregulatory failure means systemic blood pressure changes are passively transmitted to the microcirculation, and continuous CA assessment could guide individualized blood pressure targets10,25). MK 4.0 provides an integrative model unifying IIH and NPH pathophysiology as interplays of venous obstruction (MK 2.0), parenchymal mechanical stress (MK 3.0), and impaired glymphatic drainage (MK 4.0)7,9,47). Emerging therapeutic strategies targeting GS function include optimization of sedation depth to approximate physiological sleep states, pharmacological targeting of AQP4 channels and sulfonylurea receptor 1 (SUR1), creation of osmotic gradients to stimulate convective flow, and surgical drainage strategies aimed at restoring perivascular clearance10,31,48,49).

EVOLUTIONARY SYNTHESIS

Table 1 provides a comparative summary of the four evolutionary stages of the Monro-Kellie doctrine, and Table 2 lists the landmark publications defining each stage.

Table 1.

Evolutionary stages of the monro-kellie doctrine

Table 2.

Landmark publications defining each evolutionary stage

CRITICAL APPRAISAL AND LIMITATIONS

The MK 4.0 framework synthesizes decades of disparate research—cerebrovascular autoregulation, venous physiology, glymphatic science, and neuromonitoring technology—into a coherent clinical paradigm that emphasizes physiological individualization over population-based thresholds, aligning with precision medicine in critical care. However, significant limitations warrant acknowledgment. TBI—the primary target of MK 4.0—is among the most heterogeneous of critical illness entities, making interventional trial design extraordinarily challenging, and the causal pathway from multimodal monitoring to improved outcomes has not been established through randomized controlled trials10). The glymphatic component rests on a relatively nascent evidence base, with human in vivo assessment remaining technically challenging and the shift edema hypothesis requiring prospective validation10,37). The B-ICONIC recommendations have not yet undergone prospective clinical validation in diverse populations40). Perhaps most critically, the overwhelming majority of TBI patients globally are managed without any form of ICP monitoring, and while MK 4.0 aspires to democratize neuromonitoring, the infrastructure, training, and equipment requirements for implementing even the noninvasive components remain substantial.

FUTURE DIRECTIONS

Research priorities include prospective multicenter trials validating the ICS concept and B-ICONIC algorithms, development of point-of-care noninvasive CPPopt estimation methods, identification of blood-based or imaging biomarkers for glymphatic dysfunction, and systematic clinical evaluation of pharmacological strategies targeting AQP4 channels, SUR1 receptors, and neuroinflammatory cascades10,37). The application of artificial intelligence to continuous multimodal monitoring represents a particularly promising frontier, as the computational complexity of simultaneously integrating ICP waveform morphology, autoregulatory status, brain oxygenation, and systemic hemodynamics exceeds human cognitive capacity for real-time decision-making50-52). Extension of MK 4.0 to other neuroemergencies—including spontaneous intracerebral hemorrhage53), SAH-associated vasospasm, malignant ischemic stroke, status epilepticus, and acute CNS infections—represents an important area for future investigation.

CONCLUSION

The Monro-Kellie doctrine has traversed a remarkable intellectual arc from Monro’s 18th-century observation to Brasil and colleagues’ 21st-century integrative framework. MK 1.0 established volume constancy; MK 2.0 revealed the dominant role of dynamic vascular—particularly venous—hemodynamics; MK 3.0 introduced brain tissue biomechanics and calvarial plasticity; and MK 4.0 synthesizes these elements with cerebrovascular autoregulation, glymphatic system physiology, and the concept of intracranial compartment syndrome into a comprehensive paradigm for personalized neurocritical care. For the clinician at the bedside, MK 4.0 delivers a clear guidance: ICP is a dynamic variable whose waveform morphology reflects compliance status, whose relationship to systemic hemodynamics is mediated by autoregulatory integrity, and whose ultimate significance for brain tissue health depends on the functional state of the glymphatic clearance system. The future of neurocritical care lies in embracing this complexity through multimodal monitoring, individualized therapeutic targets, and the democratization of advanced neuromonitoring technologies worldwide.

Article information Continued